Literature DB >> 23602415

Thirty-day mortality in UK patients with community-onset and hospital-acquired meticillin-susceptible Staphylococcus aureus bacteraemia.

M Melzer1, C Welch.   

Abstract

BACKGROUND: The difference in mortality between patients with community-onset and hospital-acquired Staphylococcus aureus infections has rarely been described and where it has, results have been conflicting. AIM: To determine 30-day mortality in consecutive patients with meticillin-susceptible Staphylococcus aureus (MSSA) bacteraemia and the association between community-onset infection and outcome.
METHODS: From August 2007 to July 2011, demographic, clinical and microbiological data were prospectively collected on patients with MSSA bacteraemia. Patients were followed until death, hospital discharge or recovery from infection. Multivariate logistic regression was used to determine the association between community-onset infection and 30-day mortality.
FINDINGS: A total of 403 bacteraemic episodes occurred in 392 patients. Overall, there were 44 deaths (11.2%; 95% confidence interval: 7.9-14.0%) at 7 days and 101 deaths (25.8%; 21.5-30.4%) at 30 days. The difference in 30-day mortality between patients with community-onset and hospital-acquired infection was 71/256 (27.7%) versus 31/147 21.1%). Community-onset infection more frequently caused infective endocarditis (13/14, 92.9%), vertebral osteomyelitis (12/13, 92.3%) and skin and soft tissue infection (61/71, 85.9%) whereas intravascular catheter-associated infections were predominantly hospital-acquired (60/82, 73.2%). Age, Pitt score, Charlson comorbidity index (CCI), specific sites of infection (skin and soft tissue, lower respiratory tract and peripheral joints) and delay in appropriate treatment were strongly associated with 30-day mortality. In multivariate analysis, after adjustment for age, CCI and delay in appropriate treatment, community-onset infection was strongly associated with 30-day mortality (odds ratio: 1.59; 95% confidence interval: 0.91-2.80).
CONCLUSIONS: Compared with hospital-acquired MSSA bacteraemic infection, community-onset infection was associated with worse 30-day outcomes. Hospital-acquired MSSA bacteraemic infections were rarely metastatic, frequently associated with medical devices and patients had better outcomes.
Copyright © 2013. Published by Elsevier Ltd.

Entities:  

Mesh:

Year:  2013        PMID: 23602415     DOI: 10.1016/j.jhin.2012.12.013

Source DB:  PubMed          Journal:  J Hosp Infect        ISSN: 0195-6701            Impact factor:   3.926


  21 in total

1.  Infection in older adults: a qualitative study of patient experience.

Authors:  Abigail Moore; Sara McKelvie; Margaret Glogowska; Dan Lasserson; Gail Hayward
Journal:  Br J Gen Pract       Date:  2020-04-30       Impact factor: 5.386

2.  IL-10 Plays Opposing Roles during Staphylococcus aureus Systemic and Localized Infections.

Authors:  John M Leech; Keenan A Lacey; Michelle E Mulcahy; Eva Medina; Rachel M McLoughlin
Journal:  J Immunol       Date:  2017-02-06       Impact factor: 5.422

3.  Microbiome-Independent Effects of Antibiotics in a Murine Model of Nosocomial Infections.

Authors:  Keenan A Lacey; Sandra Gonzalez; Frank Yeung; Gregory Putzel; Magdalena Podkowik; Alejandro Pironti; Bo Shopsin; Ken Cadwell; Victor J Torres
Journal:  mBio       Date:  2022-05-25       Impact factor: 7.786

4.  Small Molecule Inhibitors Limit Endothelial Cell Invasion by Staphylococcus aureus.

Authors:  Diana Cordero; Christopher R Fullenkamp; Rachel R Pelly; Katie M Reed; Lindy M Caffo; Ashley N Zahrt; Micaleah Newman; Sarah Komanapalli; Evan M Niemeier; Derron L Bishop; Heather A Bruns; Mark K Haynes; Larry A Sklar; Robert E Sammelson; Susan A McDowell
Journal:  Curr Pharm Biotechnol       Date:  2014       Impact factor: 2.837

5.  Activation of Human Vδ2+ γδ T Cells by Staphylococcus aureus Promotes Enhanced Anti-Staphylococcal Adaptive Immunity.

Authors:  Andrew J R Cooper; Stephen J Lalor; Rachel M McLoughlin
Journal:  J Immunol       Date:  2020-07-10       Impact factor: 5.422

6.  The updated Charlson comorbidity index is a useful predictor of mortality in patients with Staphylococcus aureus bacteraemia.

Authors:  H G Ternavasio-de la Vega; F Castaño-Romero; S Ragozzino; R Sánchez González; M P Vaquero-Herrero; M Siller-Ruiz; G Spalter-Glicberg; C Ramírez-Baum; S Rodríguez-Rodríguez; J E García-Sánchez; I García-García; M Marcos
Journal:  Epidemiol Infect       Date:  2018-09-03       Impact factor: 4.434

Review 7.  Staphylococcus aureus Colonization: Modulation of Host Immune Response and Impact on Human Vaccine Design.

Authors:  Aisling F Brown; John M Leech; Thomas R Rogers; Rachel M McLoughlin
Journal:  Front Immunol       Date:  2014-01-08       Impact factor: 7.561

8.  Mortality predictors of Staphylococcus aureus bacteremia: a prospective multicenter study.

Authors:  Mesut Yilmaz; Nazif Elaldi; İlker İnanç Balkan; Ferhat Arslan; Ayşe Alga Batırel; Mustafa Zahir Bakıcı; Mustafa Gokhan Gozel; Sevil Alkan; Aygül Doğan Çelik; Meltem Arzu Yetkin; Hürrem Bodur; Melda Sınırtaş; Halis Akalın; Fatma Aybala Altay; İrfan Şencan; Emel Azak; Sibel Gündeş; Bahadır Ceylan; Recep Öztürk; Hakan Leblebicioglu; Haluk Vahaboglu; Ali Mert
Journal:  Ann Clin Microbiol Antimicrob       Date:  2016-02-09       Impact factor: 3.944

9.  Impact of prior healthcare-associated exposure on clinical and molecular characterization of methicillin-susceptible Staphylococcus aureus bacteremia: results from a retrospective cohort study.

Authors:  Pao-Yu Chen; Yu-Chung Chuang; Jann-Tay Wang; Shan-Chwen Chang
Journal:  Medicine (Baltimore)       Date:  2015-02       Impact factor: 1.889

10.  Memory Th1 Cells Are Protective in Invasive Staphylococcus aureus Infection.

Authors:  Aisling F Brown; Alison G Murphy; Stephen J Lalor; John M Leech; Kate M O'Keeffe; Micheál Mac Aogáin; Dara P O'Halloran; Keenan A Lacey; Mehri Tavakol; Claire H Hearnden; Deirdre Fitzgerald-Hughes; Hilary Humphreys; Jérôme P Fennell; Willem J van Wamel; Timothy J Foster; Joan A Geoghegan; Ed C Lavelle; Thomas R Rogers; Rachel M McLoughlin
Journal:  PLoS Pathog       Date:  2015-11-05       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.